Pharmaceutical Quality Evaluation of Vonoprazan Film Coated Tablets: A Newly Approved and Launched First-in-Class Potassium Competitive Acid Blocker Marketed in Bangladesh
Context: Vonoprazan fumarate is the first-in-class innovative P-CAB (potassium-competitive acid blocker) authorized and launched in the Bangladeshi pharmaceutical market in June 2023. There is no study yet on the pharmaceutical quality of Vonoprazan fumarate products manufactured and marketed in Bangladesh. Systematic assessment of pharmaceutical quality parameters is a crucial part of the continuous quality improvement and monitoring of pharmaceutical products. It is also an outstanding component of pharmacovigilance and post-marketing surveillance. Objective: This study aims to assess the physicochemical quality parameters of different marketed brands of Vonoprazan fumarate available in Bangladesh. As part of quality factors, uniformity of weight, hardness, moisture content, disintegration time, identification, dissolution, and potency test were considered in the present study. Methodology: Five brands of samples of Vonoprazan fumarate tablets were randomly chosen and purchased from different pharmacies located in Dhaka, Bangladesh. Multiple in vitro tools were used to predict and scrutinize the collected medication formulations to assess and ensure product quality and patient safety. Among others, USP (United States Pharmacopeia), Apparatus 2 (Paddle System), and HPLC (High-Performance Liquid Chromatography) were used for dissolution and potency evaluation, respectively. These tests were considered to measure the actual drug content and physical properties, as well as to forecast how specific products will behave in vivo. Results: During this investigation, it was found that the tested results of the five brands of Vonoprazan fumarate tablets complied with the quality specifications described in USP 43-NF 38 (United States Pharmacopeia 43-National Formulary 38). Conclusion: All five tested samples from the five distinct brands met the acceptability standards. The products may meet patients’ demands and provide the intended therapeutic effects.
Cite this paper
Tonmoy, S. , Rahman, M. A. , Akter, T. , Akter, R. and Rafiquzzaman, M. (2025). Pharmaceutical Quality Evaluation of Vonoprazan Film Coated Tablets: A Newly Approved and Launched First-in-Class Potassium Competitive Acid Blocker Marketed in Bangladesh. Open Access Library Journal, 12, e2882. doi: http://dx.doi.org/10.4236/oalib.1112882.
Ozaki, H., Harada, S., Takeuchi, T., Kawaguchi, S., Takahashi, Y., Kojima, Y., et al. (2018) Vonoprazan, a Novel Potassium-Competitive Acid Blocker, Should Be Used for the Helicobacter Pylori Eradication Therapy as First Choice: A Large Sample Study of Vonoprazan in Real World Compared with Our Randomized Control Trial Using Second-Generation Proton Pump Inhibitors for Helicobacter Pylori Eradication Therapy. Digestion, 97, 212-218. https://doi.org/10.1159/000485097
Marabotto, E., Ziola, S., Savarino, V., Giannini, E.G., Furnari, M., Bodini, G., et al. (2020) Vonoprazan Fumarate for the Treatment of Gastric Ulcers: A Short Review on Emerging Data. Clinical and Experimental Gastroenterology, 13, 99-104. https://doi.org/10.2147/ceg.s228352
Martinucci, I., Blandizzi, C., Bodini, G., Marabotto, E., Savarino, V., Marchi, S., et al. (2017) Vonoprazan Fumarate for the Management of Acid-Related Diseases. Expert Opinion on Pharmacotherapy, 18, 1145-1152. https://doi.org/10.1080/14656566.2017.1346087
Graham, D.Y. and Dore, M.P. (2018) Update on the Use of Vonoprazan: A Competitive Acid Blocker. Gastroenterology, 154, 462-466. https://doi.org/10.1053/j.gastro.2018.01.018
Sachs, G., Shin, J.M. and Hunt, R. (2010) Novel Approaches to Inhibition of Gastric Acid Secretion. Current Gastroenterology Reports, 12, 437-447. https://doi.org/10.1007/s11894-010-0149-5
Nishida, H. (2016) Discovery of Vonoprazan Fumarate (TAK‐438) as a Novel, Potent and Long‐Lasting Potassium‐Competitive Acid Blocker. Successful Drug Discovery, 2, 215-233.
Sakurai, K., Suda, H., Ido, Y., Takeichi, T., Okuda, A., Hasuda, K., et al. (2017) Comparative Study: Vonoprazan and Proton Pump Inhibitors in Helicobacter Pylori Eradication Therapy. World Journal of Gastroenterology, 23, Article 668. https://doi.org/10.3748/wjg.v23.i4.668
Maruyama, M., Tanaka, N., Kubota, D., Miyajima, M., Kimura, T., Tokutake, K., et al. (2017) Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Linehelicobacter Pylorieradication: A Randomized Controlled Trial. Canadian Journal of Gastroenterology and Hepatology, 2017, 1-7. https://doi.org/10.1155/2017/4385161
Miftahussurur, M., Pratama Putra, B. and Yamaoka, Y. (2020) The Potential Benefits of Vonoprazan as Helicobacter Pylori Infection Therapy. Pharmaceuticals, 13, Article 276. https://doi.org/10.3390/ph13100276
Saleh, A.M., El-Kosasy, A.M. and Fares, N.V. (2023) UV Spectrophotometric Method Development and validation of Vonoprazan Fumarate in Bulk and Pharmaceutical Dosage Form; Green Profile Evaluation via Eco-Scale and GAPI Tools. Egyptian Journal of Chemistry, 66, 141-148.
Reza, M.A., Bhowmik, U.K., Tushi, S.A., Ghosh, N., Sahana, N.C., Islam, M.A., et al. (2024) Pharmacokinetic Comparison and Bioequivalence Evaluation of Two 20-Mg Vonoprazan Fumarate Tablets in Bangladeshi Healthy Male Subjects. Journal of Biosciences and Medicines, 12, 230-243. https://doi.org/10.4236/jbm.2024.128018
Goodwin, D.J., van den Ban, S., Denham, M. and Barylski, I. (2018) Real Time Release Testing of Tablet Content and Content Uniformity. International Journal of Pharmaceutics, 537, 183-192. https://doi.org/10.1016/j.ijpharm.2017.12.011
Karande, A.D., Heng, P.W.S. and Liew, C.V. (2010) In-Line Quantification of Micronized Drug and Excipients in Tablets by near Infrared (NIR) Spectroscopy: Real Time Monitoring of Tabletting Process. International Journal of Pharmaceutics, 396, 63-74. https://doi.org/10.1016/j.ijpharm.2010.06.011
Hudson-Curtis, B. and Novick, S. (2016) Assessing Content Uniformity. In: Zhang, L., Eds., Nonclinical Statistics for Pharmaceutical and Biotechnology Industries, Springer, 631-651. https://doi.org/10.1007/978-3-319-23558-5_24
Patel, S. and Sun, C.C. (2016) Macroindentation Hardness Measurement—Modernization and Applications. International Journal of Pharmaceutics, 506, 262-267. https://doi.org/10.1016/j.ijpharm.2016.04.068
Chowhan, Z.T., Yang, I.C., Amaro, A.A. and Chi, L. (1982) Effect of Moisture and Crushing Strength on Tablet Friability and in Vitro Dissolution. Journal of Pharmaceutical Sciences, 71, 1371-1375. https://doi.org/10.1002/jps.2600711215
Molokhia, A.M., Al-Shora, H.I. and Hammad, A.A. (1987) Aging of Tablets Prepared by Direct Compression of Bases with Different Moisture Content. Drug Development and Industrial Pharmacy, 13, 1933-1946. https://doi.org/10.3109/03639048709068700
Markl, D. and Zeitler, J.A. (2017) A Review of Disintegration Mechanisms and Measurement Techniques. Pharmaceutical Research, 34, 890-917. https://doi.org/10.1007/s11095-017-2129-z
Silva, D.A., Webster, G.K., Bou-Chacra, N. and Löbenberg, R. (2018) The Significance of Disintegration Testing in Pharmaceutical Development. Dissolution Technologies, 25, 30-38. https://doi.org/10.14227/dt250318p30
Shah, V.P., Tymes, N.W. and Skelly, J.P. (1989) In Vitro Release Profiles of Clonidine Transdermal Therapeutic Systems and Scopolamine Transdermal Patches. Pharmaceutical Research, 6, 346-351.
Guidance, F.D. (1995) Guidance for Industry, Immediate Release Solid Oral Dosage Forms Scale-Up and Post Approval Changes: Chemistry, Manufacturing, and Controls. In Vitro Dissolution Testing, and in Vivo Bioequivalence Documentation (SUPAC-IR). US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER).
Food US and Drug Administration (1997) Guidance for Industry: Modified Release Solid Oral Dosage Forms Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls, in Vitro Dissolution Testing, and in Vivo Bioequivalence Documentation.
Anand, O., Yu, L.X., Conner, D.P. and Davit, B.M. (2011) Dissolution Testing for Generic Drugs: An FDA Perspective. The AAPS Journal, 13, 328-335. https://doi.org/10.1208/s12248-011-9272-y
Weatherall, M. (1966) The Meaning and Importance of Drug Potency in Medicine. Clinical Pharmacology & Therapeutics, 7, 577-582. https://doi.org/10.1002/cpt196675577
Risha, P.G., Vervaet, C., Vergote, G., Bortel, L.V. and Remon, J.P. (2003) Drug Formulations Intended for the Global Market Should Be Tested for Stability under Tropical Climatic Conditions. European Journal of Clinical Pharmacology, 59, 135-141. https://doi.org/10.1007/s00228-003-0587-1
